CEA-targeted CAR-T cells
Phase 1Cell therapy
CEA-targeted CAR-T cells is one of 48 biologic programs targeting Colorectal Cancer. It is currently in Phase 1.
2
Indications
6
Total Trials
5
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Eylea
RegeneronPreclinical
Emend IV
Merck & Co.Preclinical
PORTRAZZA
Eli LillyPreclinical
Ketalar
AAultman Health Foundation
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Vascepa
AAmarin Pharma Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors2 trials
Advanced Malignant Solid Tumors2 trials
Colorectal Cancer1 trial
CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07247396·12 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CEA-targeted CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details